SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials-Reference-Cited by-同舟云学术

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials

Published:2021-10-08 Issue:6 Volume:8 Page:4693-4700
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Dhingra Nitish K.¹,Mistry Nikhil²³,Puar Pankaj¹,Verma Raj⁴,Anker Stefan⁵,Mazer C. David²³⁶⁷,Verma Subodh¹³⁷⁸

Affiliation:

1. Division of Cardiac Surgery, St. Michael's Hospital University of Toronto 30 Bond Street Toronto Ontario Canada

2. Department of Anesthesia, St. Michael's Hospital University of Toronto Toronto Ontario Canada

3. Institute of Medical Sciences University of Toronto Toronto Ontario Canada

4. North York Diagnostic and Cardiac Centre Toronto Ontario Canada

5. Department of Cardiology & Berlin Institute of Health Center for Regenerative Therapies German Center for Cardiovascular Research, Partner Site Berlin, Charité‐Universitätsmedizin Berlin Berlin Germany

6. Department of Physiology University of Toronto Toronto Ontario Canada

7. Keenan Research Center in the Li Ka Shing Knowledge Institute of St. Michael's Hospital University of Toronto Toronto Ontario Canada

8. Department of Pharmacology and Toxicology University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13645

Reference17 articles.

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

3. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

4. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

5. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial;BMJ Open;2024-08

2. Molecular Basis of Cardiomyopathies in Type 2 Diabetes;International Journal of Molecular Sciences;2024-07-29

3. The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview;International Journal of Molecular Sciences;2024-07-14

4. Sodium-Glucose Cotransporter 2 Inhibitors During Cancer Therapy: Benefits, Risks, and Ongoing Clinical Trials;Current Oncology Reports;2024-07-11

5. Ventricular remodeling and hemodynamic changes in heart failure patients with non-ischemic dilated cardiomyopathy following dapagliflozin initiation;The Egyptian Heart Journal;2024-06-18